Platelet and Red Blood Cell Utilization and Transfusion Independence in Umbilical Cord Blood and Allogeneic Peripheral Blood Hematopoietic Cell Transplants  by Solh, Melhem et al.
From the 1
and 2
Unive
Financial d
Correspon
and M
cology
Code
(e-ma
Received J
 2011 Am
1083-8791
doi:10.101
710Platelet and Red Blood Cell Utilization and Transfusion
Independence in Umbilical Cord Blood and Allogeneic
Peripheral Blood Hematopoietic Cell Transplants
Melhem Solh,1 Claudio Brunstein,1 Shanna Morgan,2 Daniel Weisdorf1Allogeneic hematopoietic cell transplantation (HCT) recipients have substantial transfusion requirements.
Factors associated with increased transfusions and the extent of blood product use in umbilical cord blood
(UCB) recipients are uncertain. We reviewed blood product use in 229 consecutive adult recipients of
allogeneic HCTat the University of Minnesota: 147 with leukemia, 82 lymphoma or myeloma; 58% received
unrelated UCB and 43% sibling donor peripheral blood stem cell (PBSC) grafts. Although neutrophil recov-
ery was prompt (UCB median 17, range: 2-45 days, and PBSC 14, range: 3-34 days), only 135 of 229 (59%
cumulative incidence) achieved red blood cell (RBC) independence and 157 (69%) achieved platelet
independence by 6 months. Time to platelet independence was prolonged in UCB recipients (median
UCB 41 versus PBSC 14 days) and in patients who had received a prior transplant (median 48 versus 32
days). Patients who received UCB grafts required more RBC through day 60 post-HCT (mean UCB 7.8
(95% confidence interval [CI] 6.7-8.9) versus PBSC 5.2 (3.7-6.7) transfusions, P 5 .04), and more platelet
transfusions (mean 25.2 (95% CI 22.1-28.2) versus 12.9 (9.4-16.4), P\.01) compared to PBSC recipients.
Patients receiving myeloablative (MA) conditioning required more RBC and platelet transfusions during
the first 2 months post-HCT compared to reduced-intensity conditioning (RIC) (7.4 versus 6.2, P 5 .30
for RBC; 23.2 versus 17.5, P 5 .07 for platelets). Despite prompt neutrophil engraftment, UCB recipients
had delayed platelet recovery as well as more prolonged and costly blood product requirements. Enhanced
approaches to accelerate multilineage engraftment could limit the transfusion-associatedmorbidity and costs
accompanying UCB allotransplantation.
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Over the past decade, there has been an increase in
the use of allogeneic hematopoietic stem cell trans-
plants (HCT) to treat hematologic malignancies and
life-threatening nonmalignant hematologic disorders.
This increase is attributable to newer techniques, safer
preparative regimens, and expanded use of peripheral
blood stems cells (PBSC) and umbilical cord blood
(UCB) as graft sources [1]. Even using newer, lessDivision ofHematology, Oncology, andTransplantation;
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receive frequent blood products as part of their sup-
portive therapy [2]. In light of substantial cost and
some risk associated with blood product use, we pur-
sued a detailed study of red blood cell (RBC) and plate-
let (PLT) transfusion needs during an HCT course.
Limited available data on the extent of blood product
utilization after HCT include Osterwalder et al. [2]
reporting 39 HCT patients needing a range of 1 to
32 RBC and 1 to 11 PLT transfusions, and Pihlstedt
et al. [3] describing 182 allogeneic transplants patients
receiving 1 to 63 RBC and 2 to 394 PLT transfusions.
We reviewed the blood product use in 229 consecutive
patients at our institution and assessed factors associ-
ated with greater transfusion needs.MATERIALS AND METHODS
Patients and Methods
Using prospectively collected data from the Uni-
versity of Minnesota Blood and Marrow Transplant
Database, we reviewed demographics and HCT
Table 1. Patient Demographics and Graft Source
N Percent
Total 229 100%
Graft source and conditioning intensity
PBSC RIC 46 20%
PBSC myeloablative 52 23%
UCB RIC 72 31%
UCB myeloablative 59 26%
Sex
Male/female 140/89 61%/39%
Race
White/other 196/31 86%/14%
Transplant number
1 190 83%
>1 39 17%
Diagnosis
Leukemia 147 64%
Lymphoma/myeloma 82 36%
PBSC indicates peripheral blood stem cell; RIC, reduced-intensity
conditioning; UCB, umbilical cord blood.
Biol Blood Marrow Transplant 17:710-716, 2011 711Red Blood Cell Utilization in allogeneic Peripheral HCTcomplications in 229 consecutive adult patients who
underwent allogeneic HCT. This was supplemented
with complete and detailed transfusion data for the
initial 3 months after HCT. We also detailed the pre-
parative regimen, gender, race, and number of prior
transplants to determine associated factors that may
have altered their blood product utilization, RBC
and PLT engraftment, and time to transfusion inde-
pendence. The patients were divided into 4 groups
based on the underlying disease: leukemia (n 5 147),
lymphoma/myeloma (n5 82), nonmalignant disorders
(43), and Fanconi anemia (7). The formal analysis was
limited to the more homogeneous subset of patients
with either leukemia or lymphoma/myeloma (N5 229).
The patients received a preparative regimen classified as
eithermyeloablative (MA) plus filgrastim-mobilized sib-
ling donor PBSC, reduced-intensity conditioning (RIC)
plus sibling donor PBSC, UCB MA, or UCB RIC.
Patients were given prophylaxis for graft-versus-host
disease (GVHD) and supportive care based on the de-
fined institutional guidelines and active investigational
protocols.
Transfusion Support and Endpoints
Prophylactic platelet transfusions were adminis-
tered to nonbleeding patients at a pretransfusion trigger
of\10,000/mL unless additional risks of bleeding (eg,
mucositis, plasma coagulation disorder, sepsis) were
present. Treatment for therapeutic bleeding followed
WHO guidelines. Red blood cell transfusions were
administered for Hb\8 g/dL. All products were irradi-
ated in vitro with 25 Gy prior to transfusion.
Transfusion independence was defined as the day
of the last post-HCT PLT transfusion with no PLT
transfusions in the following 7 days. RBC transfusion
independence was defined as the day of the last RBC
transfusion with no transfusion in the following 30
days. The total number of transfusion episodes and
the total transfused PLT and RBC units during the
transplant period were determined. Incidence and
time to hematologic and RBC independence was de-
termined for the total (N 5 229) and separately for
the leukemia (n 5 147) and lymphoma/myeloma
(n 5 82) subgroups.
Statistical Analysis
Comparison of patients’ characteristics used the c2
test or Fisher’s exact test for categoric variables, and
Wilcoxon’s rank-sum test for continuous variables.
The cumulative incidence of RBC and PLT indepen-
dence was used by treating deaths from other causes as
competing risks. Univariate analysis was performed for
differences in PLT independence and RBC indepen-
dence, whereas risk factor analysis of time toRBC trans-
fusion independence and time to PLT transfusion
independence was performed using competing riskregression analysis. Risk factors considered included:
donor and graft source, conditioning regimen
(myeloablative versus RIC), race, gender, and HCT
number for those with a prior HCT. All P values re-
ported were 2-sided and P values\.05 were considered
statistically significant. Marginal mean was used to
report on the monthly and total number of PLT and
RBC units used. Marginal mean is defined as the
weighted average of the conditionalmeans,withweights
equal to the probability of being in the subgroup deter-
mined by the corresponding value of the conditioning
variable. Data analysis was performed using SAS soft-
ware, version 8.0. The University of Minnesota institu-
tional review board approved the data collection and
analysis.RESULTS
Patient Characteristics
We studied 229 consecutive allogeneic adult HCT
recipients with hematologic malignancies receiving
either PBSC or UCB grafts (Table 1). Of these, 140
were males (61%), 196 were Caucasian (86%), 131
(57%) received UCB, and 98 (43%) PBSC grafts. One
hundred eighteen (52%) received RIC and 111 (48%)
MA conditioning. Thirty-nine (17%) had a previous
(38 autologous; 1 allogeneic) HCT. In the entire group,
hematopoietic reconstitution manifest as sustained
neutrophil recovery was prompt (UCB median 17,
range: 2-45 days, and PBSC median 14, range: 3-34
days).
Transfusion Independence
Time to transfusion independence by donor type
and conditioning regimen subgroups is shown in
Table 2. RBC independence occurred at a median of
44 (range: 7-141) days and PLT independence at a me-
dian of 33 (range: 11-172) days after HCT. Although
Table 2. Time to RBC and Platelet Transfusion Independence
RBC Independence Platelet Independence
N
RBC Independent
by 6 months (n)
Median time to
independence
(range, days)
Platelet Independent
by 6 months (n)
Median time to
independence
(range, days)
Total 229 135 44 (7-141) 157 33 (11-172)
Graft source
UCB 131 76 44.5 92 41
PBSC 98 59 44 65 14
Conditioning
RIC 118 68 41.5 80 29
Myeloablative 111 67 55 77 35
Transplant number
>1 39 17 44 21 48
1 190 118 44.5 136 32
RBC indicates red blood cells; PBSC, peripheral blood stem cells; UCB, umbilical cord blood.
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upon donor source or HCT number, it was somewhat
longer after MA conditioning (median 55 [range:
9-141] days versus 42 [7-127] days, P5 .43) and among
women (56 days versus 42 days, P 5 .26). The time to
PLT independence was prolonged in UCB recipients
compared to PBSC, although it did not reach statisti-
cal significance (41 [range: 18-172] days versus 14 [11-
161] days, P 5 .52) and in recipients of second HCT
(48 days versus 32 days, P 5 .09). By 6 months after
HCT, only 76 of 131 (58%) UCB recipients versus.
59 of 98 (60%) PBSC recipients were independent of
RBC transfusions, and 92 of 131(70%) UCB and 65
of 98 (66%) PBSC were independent of PLT support.
Transfusion Independence within Disease
Subgroups
Because either diagnosis or prior therapies con-
founded the assessmentof transfusionneeds,we analyzed
the cumulative transfusion requirements of patients with
leukemia and with myeloma/lymphoma separately. Of
147 patients with leukemia, 98 (67%) received UCB
grafts, 90 (62%) received MA conditioning regimen,
and 126 patients (86%) had no prior transplant.
Eighty-three patients (56%) achieved RBC indepen-
dence within 6 months of transplant with a median
time to RBC independence of 49 (range: 11-160) days.
Time to RBC independence was somewhat longer in fe-
males (63 versus 43 days, P 5 .27) and after MA condi-
tioning (56 versus 43 days, P 5 .21) but did not reach
statistical significance. Ninety-five patients (65%)
achieved PLT independence by 6 months with a median
time of 35 days. Time to PLT independence was longer
yet not significant afterUCB (43 versus 25 days,P5 .43)
and in recipients of second transplants (57 days versus 34
days, P5 .16). However, within the leukemia group, we
observednostatistically significantdifferences in the time
toPLT transfusion independence based ondonor source
(Figure 1), conditioning regimen, race, gender, or num-
ber of transplants. Among the patients who receivedRIC conditioning,median times toRBCandPLT trans-
fusion independence in theUCBsubgroupwere41.5 and
39 days and were not different from the PBSC subgroup
(58 and 12 days).
Of 82 patients with lymphoma/myeloma, 32 (39%)
had UCB grafts, 21 (26%) had MA conditioning, and
18 (22%) had received a prior transplant. Fifty-two
patients (63%) achieved RBC independence by 6
months, with a median time to independence of 43
days. The median time to RBC independence was
somewhat longer in females (52 versus 35 days,P5 .27),
recipients of UCB (40 versus 10 days, P 5 .10), those
with prior HCT (54 versus 35 days, P 5 .02), and fol-
lowing MA conditioning (47 versus 41 days, P 5 .03).
Sixty-two patients (75%) achieved PLT independence
by 6 months, with a median time of 21 days. The time
to PLT independence was longer yet not statistically
significant in recipients of UCB versus PBSC (40 ver-
sus 10 days, P 5 .16) and also in those with a prior
transplant (48 versus 15 days, P 5 .01). There were
no differences in time to PLT independence based
on conditioning regimen (21 days for myeloablative
versus 20 days for RIC) or other clinical factors.
Multivariate Regression Analysis of Transfusion
Independence
Using competing risk regression analysis, we eval-
uated factors influencing the time to platelet or RBC
independence in the different disease subgroups. In
the lymphoma/myeloma group, therewas a statistically
significant longer time to RBC independence using
myeloablative conditioning (P 5 .03) and following
second HCTs (P 5 .02). Similarly, time to PLT inde-
pendence was significantly longer after MA condition-
ing (P 5 .01) and second HCT (P 5 .009). There was
no significant difference based on the graft source
(UCB versus PBSC, P 5 .16). However, within the
larger subgroup of patients with leukemia, no factors
were independently associated with the time to achieve
either RBC or PLT independence.
Figure 1. Time to RBC and platelet independence. In leukemia pa-
tients, shown is the cumulative incidence of the time to transfusion in-
dependence (untransfused Hb .8 g/dL; PLT .20,000/mL) in recipients
of UCB or sibling donor PBSC grafts.
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Leukemia
Patients in the larger leukemia subgroup were
further studied to detail the number of transfusions re-
quired during each of the first 3 months after HCT.
The marginal mean number of RBC and PLT transfu-
sions received in each month was compared in cohorts
defined by thegraft source (UCBversusPBSC) and con-
ditioning regimen intensity (MA versus RIC) (Table 3).
Compared to PBSC, UCB recipients required
a greater number of RBC transfusions during each of
the first 3 months posttransplantation, and this reached
statistical significance for months 2 and 3. Patients
who received MA conditioning also had a greater need
for PLT transfusions (Table 3). Similarly, during each
of the first 3 months post-HCT, UCB recipients re-
quired significantly more PLT transfusions than PBSC
(P \ .01). The marginal mean and total number of
both PLT and RBC transfusions were significantly
higher in UCB recipients during the first 3 monthsTable 3. Marginal Mean RBC and Platelet Transfusions (HCT for L
Month 1
N Mean 95% CI P*
All 146 RBC 4.5 (4.0-5.0)
Platelets 14.5 (13.6-15.7)
Graft source
UCB 98 RBC 4.8 (4.2-5.4) .18*
PBSC 48 3.9 (3.1-4.8)
UCB Platelets 16.1 (14.7-17.6) <.01
PBSC 11.0 (8.7-13.2)
Conditioning intensity
Myeloablative 90 RBC 4.8 (4.3-5.4) .16
RIC 56 4.0 (3.1-4.9)
Myeloablative Platelets 15.8 (14.5-17.2) <.01
RIC 12.1 (9.6-14.6)
CI indicates confidence interval; RIC, reduced-intensity conditioning; RBC indi
cord blood; HCT, hematopoietic cell transplant.
*P values represent each time point comparison of the marginal mean of RBCpost-HCT (Figure 2). MA conditioning was associated
with significantly increased PLT requirements during
month 1, and a similar trend in months 2 and 3, but
RBC requirements were similar in both conditioning
groups.DISCUSSION
RecipientsofHCToftenhave substantial transfusion
requirements, particularly in the minority with either
delayed recovery of hematopoiesis, alloimmunization to
PLTs, or GVHD. Even using standard thresholds for
blood product administration such as RBC for Hb\8
g/dL or PLT for a count\10,000/mL, transfusion needs
vary substantially. The PLADO trial questioned the ne-
cessity of PLT prophylactic transfusions by noting that
major bleeding episodes are infrequent and not clearly
associated with PLT counts, even in the severely throm-
bocytopenic patient [4]. The majority of hospitalized
allogeneic HCT recipients are vulnerable to infections
or febrile, have added risks of bleeding because of muco-
sitis, plasma coagulation abnormalities, or similar com-
plications that suggest a need for a higher PLT count
trigger for transfusion.We restricted our detailed analy-
sis of total blood product usage and time to transfusion
independence in allogeneicHCTpatients with leukemia
because they are usually multiply transfused and possibly
alloimmunized prior to HCT.
Transfusion guidelines in HCT patients are tradi-
tionally extrapolated from other subgroups of pancyto-
penic patients, as specific data from HCT are less well
defined [5-8]. The threshold for PLT transfusion in
HCT recipients has changed over time, with earlier
guidelines suggesting 20,000/mL as an acceptable
threshold for prophylaxis [9]. Several reports showed
that a platelet threshold of less than 20,000/mL can be
safely used in acute leukemia and HCT recipients
[10-12]. In some reports, lowering the transfusioneukemia)
Month 2 Month 3
Mean 95% CI P Mean 95% CI P*
7.0 (6.0-7.9) 7.7 (6.6-8.8)
21.2 (18.7-23.8) 23.7 (20.2-27.2)
7.8 (6.7-8.9) .04 8.9 (7.5-10.2) .02
5.2 (3.7-6.7) 5.4 (3.7-7.0)
25.2 (22.1-28.2) <.01 28.5 (24.1-32.8) <.01
12.9 (9.4-16.4) 13.6 (9.3-17.9)
7.4 (6.3-8.5) .30 8.4 (7.0-9.8) .17
6.2 (4.6-7.8) 6.4 (4.6-8.3)
23.2 (20-26) .07 26.4 (22.2-30.6) .07
17.5 (12.9-22.2) 18.4 (12.5-24.2)
cates red blood cells; PBSC, peripheral blood stem cells; UCB, umbilical
and platelet transfusions for graft source and conditioning intensity.
Figure 2. Marginal mean of platelet (A) and RBC (B) transfusion over
time. Shown are the marginal means of cumulative PLT (A) and RBC (B)
transfusions over the first 6 months post-HCT for patients with leuke-
mia. UCB recipients have significantly greater mean PLT (P\ .01) and
RBC (P 5 .02) transfusion needs compared to PBSC.
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transplant recipients did not increase severe bleeding
or death because of bleeding, but reduced PLT use by
about 25% [13]. The current threshold of 10,000/mL
is used by most centers to initiate prophylactic PLT
transfusions [5,8,14].
The demand for RBC transfusion in HCT has de-
creased in recent years. This could be related to the use
of less intensive regimens and implementing granulo-
cyte colony stimulating factor (G-CSF) into the trans-
plant process, hence decreasing oral or gastrointestinal
bleeding episodes related to prolonged mucositis [15].
A transfusion trigger of Hb\8 g/dL is used at our
and most centers, although higher thresholds are indi-
cated for patients with cardiovascular comorbidities
[16]. Higher thresholds have also been suggested for
transplant recipients with acute GVHD (aGVHD),delayed engraftment, major ABO incompatibility, and
high-risk malignancies [3].
RIC has been more widely used in recent years be-
cause of the decreased risk of associated toxicities and
the reliance on a more pronounced graft-versus-tumor
effect for cancer control [17]. Prebet et al. [18] reported
data onPLTrecovery and transfusion needs in145 adult
allogeneic sibling donor HCT recipients with RIC.
PLT recovery (.20,000/mL) was seen at a median of 9
days with 68% of the patients demonstrating a PLT
count .100,000/mL by day 1100. A lower PLT count
prior to conditioning and the presence of aGVHD
(grade III-IV) significantly influenced day 1100 PLT
recovery and PLT transfusion needs. Similarly, the me-
dian time to PLT independence in our RIC cohort is 14
days, even with 61% receiving UCB grafts, which may
delay engraftment compared to other donor sources
[19]. Other unrelated donor sources andMA condition-
ing are also associated with delayed PLT recovery.
Median time to more robust PLT recovery
(.50,000/mL) in UCB HCT has been reported to be
as late as day 190; and the success was related to the
patient’s age, diagnosis, graft cell dose infused, post-
HCT infection, and the development of GVHD
[20]. Although the incidence of PLT transfusion inde-
pendence at 6 months did not differ, we observed that
UCB grafts led to delayed PLT independence com-
pared to other donor sources [21] and an overall
greater transfusion burden. Delayed engraftment,
a precursor to PLT recovery in UCB recipients, has
been associated with a lower CD341 cell dose, recipi-
ent weight, and HLA disparity [22].
We also observed less frequent and later transfu-
sion independence in recipients having a prior HCT.
In our cohort of 39 repeat HCT recipients, this delay
could be because of the graft source, prior marrow
stromal damage from extensive prior treatment, or
their specific diagnoses (most often secondary acute
myelogenous leukemia [AML]/myelodysplastic syn-
drome [MDS]), although we could not fully character-
ize the pathogenesis of delayed PLT recovery in this
small subgroup. In comparison, Baron et al. [23] re-
ported on 147 patients receiving a very low-intensity,
nonmyelablative regimen followed by either matched
related (n 5 62) or unrelated (n 5 85) allogeneic
RIC HCT because of disease relapse after a prior
autologous or allogeneic transplant who needed only
a median of 0 and 4 for PLT and RBC transfusions, re-
spectively. Martino et al. [24] reported a median of 11
days to obtain a PLT count of.20,000/mL in a similar
group of sibling donor RIC HCT recipients who had
relapsed after a prior autologous transplant.
RBC transfusion needs in the first 60 days after
allogeneic HCT were observed at a median of 4
RBC units for RIC and 12 units for MA conditioning
[25]; slightly more in patients with leukemia (6 units
for RIC and 13 units for MA). Another report
Biol Blood Marrow Transplant 17:710-716, 2011 715Red Blood Cell Utilization in allogeneic Peripheral HCTdescribed infusion of only 2 RBC units after RIC [26].
Factors associated with increased RBC transfusion
requirements include aGVHD, ABO incompatible
donor, and high-risk malignancy [3]. Our data show
that both MA conditioning and UCB grafts are associ-
ated with higher transfusion requirements.
We previously analyzed the increased cost for UCB
compared to matched related or unrelated donor HCT
with 11% to 14% of the costs in different HCT settings
attributable to transfusion product needs [27]. Our cur-
rent data show that patients receiving UCB grafts
required ameanof 15extraPLTtransfusions and4extra
RBC transfusions during the first 3 months post-HCT.
Based on costs from theCenters forMedicare andMed-
icaid Services 2007 reimbursement report on blood
transfusion (leukoreduced irradiated RBC unit: $227;
apheresis PLT irradiated leukoreduced: $614), the in-
crease in transfusion requirements seenwithUCBgrafts
augmented transfusion-associated costs by approxi-
mately $11,000 during the first 3 months post-HCT,
equating to $122 per day, plus additional costs for pre-
medications, infusion supplies, and the nursing effort
for transfusion and monitoring.
Our observations suggest that RBC and PLT trans-
fusion requirements are somewhat increased with UCB
grafts, although are moderated by RIC HCT. The use
of UCB as a donor source may delay transfusion inde-
pendence and modestly increase the overall costs of
HCT as well. Additional efforts to improve transfusion
practices and augment hematopoietic recovery may
limit both the transfusion burden and the costs of
prolonged RBC and PLT transfusions.ACKNOWLEDGMENTS
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